Presentation of Phase IIa Results for Cytos Biotechnology's Hypertension Vaccine at the American Heart Association Scientific Ses...(of disease-related molecules(antigens) o...)

This foregoing press release may contain forward-looking statements that include words or phrases such as "designed", "potential", "would", "should", "could", "promising", "suggest", "aim", "intend" or other similar expressions. These forward-looking statements are subject to a variety of significant uncertainties, including scientific, business, economic and financial factors, and therefore actual results may differ significantly from those presented. There can be no assurance that any other therapeutic entities will enter clinical trials, that clinical trial results will be predictive for future results, that therapeutic entities will be the subject of filings for regulatory approval, that any drug candidates will receive marketing approval from the U.S. Food and Drug Administration or equivalent regulatory authorities, or that drugs will be marketed successfully. Against the background of these uncertainties readers should not rely on forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of Cytos Biotechnology AG.

For further information please contact:

Claudine Blaser, PhD

Director Corporate Communications

Cytos Biotechnology AG, Wagistrasse 25, CH-8952 Schlieren,

Switzerland

Phone: +41-44-733-47-20,

e-Mail: claudine.blaser@cytos.com,

Website: http://www.cytos.com